Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The Broad Institute Inc. currently manages 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters is widely distributed across 8 distinct examiners and 8 distinct art units. The presence of 8 distinct examiners for 8 pending office actions indicates that each application is receiving review from a different individual within the patent office.
Jared Barsky is the busiest examiner for this portfolio, currently handling 1 pending office action. The fact that 8 distinct examiners and 8 distinct art units are involved for 8 pending office actions indicates that each application is being reviewed in a unique technical and administrative context. This suggests a diverse range of biological or pharmaceutical innovations that do not overlap in their specific patent office classifications.
For the practitioner, this distribution of 8 pending office actions across 8 distinct examiners means that no single examiner's habits will dominate the portfolio's current outlook. Each of the 8 distinct art units will likely have its own specific examination culture, requiring a tailored approach for each of the 8 pending office actions. The company must manage 8 separate examiner relationships across 8 different technical divisions simultaneously.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| KOVACH, KARA NICOLE | 1 | 85.7% | +100.0% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.8% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| LAFAVE, ELIZABETH ROSE | 1 | 64.4% | +43.2% |
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 26d |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 54d |
| 18580579 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A COMPLEX BIOLOGICAL SAMPLE | KOVACH, KARA NICOLE | — |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | LAFAVE, ELIZABETH ROSE | — |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 26d |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 54d |
| 18622123 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | BARSKY, JARED | — |
| 18690382 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | PAGUIO FRISING, MICHELLE F | — |
| 18580716 | ENGINEERED TARGETING COMPOSITIONS FOR ENDOTHELIAL CELLS OF THE CENTRAL NERVOUS SYSTEM VASCULATURE AND METHODS OF USE THEREOF | LEONARD, ARTHUR S | — |
| 18580579 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A COMPLEX BIOLOGICAL SAMPLE | KOVACH, KARA NICOLE | — |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | LAFAVE, ELIZABETH ROSE | — |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | BEHARRY, ZANNA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1651 | 1 |
| 1631 | 1 |
| 1681 | 1 |
| 1627 | 1 |
| 1633 | 1 |
| 1684 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18622123 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | BARSKY, JARED | 1628 | §103 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18690382 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | PAGUIO FRISING, MICHELLE F | 1651 | §112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18580716 | ENGINEERED TARGETING COMPOSITIONS FOR ENDOTHELIAL CELLS OF THE CENTRAL NERVOUS SYSTEM VASCULATURE AND METHODS OF USE THEREOF | LEONARD, ARTHUR S | 1631 | §102§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18580579 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A COMPLEX BIOLOGICAL SAMPLE | KOVACH, KARA NICOLE | 1681 | §101§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 1627 | §102§103 | Final Rejection | 54d | Pending | Sep 01, 2023 |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 1633 | §103 | Final Rejection | 26d | Pending | Aug 09, 2023 |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | LAFAVE, ELIZABETH ROSE | 1684 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2022 |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | BEHARRY, ZANNA MARIA | 1632 | §103§112 | Final Rejection | — | Pending | Nov 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Broad Institute Inc. has 8 pending office actions as of October 2026, spread across 8 art units and 8 examiners.
Jared Barsky has the most, with 1 of The Broad Institute Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
